A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

Trial Profile

A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs Fidaxomicin (Primary)
  • Indications Clostridium infections; Diarrhoea
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Optimer Pharmaceuticals
  • Most Recent Events

    • 08 Oct 2014 Results presented at the IDWeek 2014, according to a Cubist Pharmaceuticals media release.
    • 27 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrial.gov record.
    • 27 Mar 2014 Planned End Date changed from 1 Jan 2014 to 1 Mar 2014 as reported by ClinicalTrial.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top